z-logo
open-access-imgOpen Access
Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
Author(s) -
Donald G. Munroe,
Ashwani Gupta,
Fatemeh Kooshesh,
Tejal Vyas,
Geihan Rizkalla,
Hong Wang,
Lidia Demchyshyn,
Zhijie Yang,
Rajender K. Kamboj,
Hongyun Chen,
Kirk McCallum,
Martin Sumner-Smith,
Daniel J. Drucker,
Anna Crivici
Publication year - 1999
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.96.4.1569
Subject(s) - proglucagon , glucagon like peptide 2 , enteroendocrine cell , receptor , biology , enterocyte , crypt , glucagon like peptide 1 , medicine , microbiology and biotechnology , signal transduction , endocrinology , glucagon , small intestine , biochemistry , peptide , endocrine system , hormone , type 2 diabetes , diabetes mellitus
Glucagon-like peptide 2 (GLP-2) is a 33-aa proglucagon-derived peptide produced by intestinal enteroendocrine cells. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. Moreover, GLP-2 prevents intestinal hypoplasia resulting from total parenteral nutrition. However, the mechanism underlying these actions has remained unclear. Here we report the cloning and characterization of cDNAs encoding rat and human GLP-2 receptors (GLP-2R), a G protein-coupled receptor superfamily member expressed in the gut and closely related to the glucagon and GLP-1 receptors. The human GLP-2R gene maps to chromosome 17p13.3. Cells expressing the GLP-2R responded to GLP-2, but not GLP-1 or related peptides, with increased cAMP production (EC50 = 0.58 nM) and displayed saturable high-affinity radioligand binding (Kd = 0.57 nM), which could be displaced by synthetic rat GLP-2 (Ki = 0.06 nM). GLP-2 analogs that activated GLP-2R signal transduction in vitro displayed intestinotrophic activity in vivo. These results strongly suggest that GLP-2, like glucagon and GLP-1, exerts its actions through a distinct and specific novel receptor expressed in its principal target tissue, the gastrointestinal tract.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom